OBJECTIVES: To determine whether a postoperative venous thromboembolism (VTE) is associated with a worse prognosis and/or a more advanced cancer stage and to evaluate the association between a postoperative VTE and cancer-specific survival when known prognostic factors, such as age, stage, cancer type, and type of surgery, are controlled. CONTEXT: It is unknown whether oncology patients who develop a venous thromboembolism after a complete curative resection are at the same survival disadvantage as oncology patients with a spontaneous VTE. METHODS: A retrospective case control study was conducted at Memorial Sloan-Kettering Cancer Center. Years of study: January 1, 2000, to December 31, 2005. Median follow-up: 24.9 months (Interquartile range 13.0, 43.0). All cancer patients who underwent abdominal, pelvic, thoracic, or soft tissue procedures and those who developed a VTE within 30 days of the procedure were identified from a prospective morbidity and mortality database. Overall survival (OS) was calculated for the entire cohort. In the matched cohort, OS and disease-specific survival (DSS) were calculated for stages 0 to 3 and stages 0 to 2. RESULTS: A total of 23,541 cancer patients underwent an invasive procedure and 474 (2%) had a postoperative VTE. VTE patients had a significantly worse 5-year OS compared to no-VTE patients (43.8% vs 61.2%; P < 0.0001); 205 VTE patients (stages 0-3) were matched to 2050 controls by age, sex, cancer type, stage, and surgical procedure. In this matched analysis, VTE patients continued to demonstrate a significantly worse prognosis with an inferior 5-year OS (54.7% vs 66.3%; P < 0.0001) and DSS (67.8% vs 79.5%; P = 0.0007) as compared to controls. The survival difference persisted in early stage disease (stage 0-2), with 5-year DSS of 82.9% versus 87.3% (P = 0.01). CONCLUSIONS: Postoperative VTE in oncology patients with limited disease and a complete surgical resection is associated with an inferior cancer survival. A postoperative VTE remains a poor prognostic factor, even when controlling for age, stage, cancer type, and surgical procedure further supporting an independent link between hypercoagulability and cancer survival.
OBJECTIVES: To determine whether a postoperative venous thromboembolism (VTE) is associated with a worse prognosis and/or a more advanced cancer stage and to evaluate the association between a postoperative VTE and cancer-specific survival when known prognostic factors, such as age, stage, cancer type, and type of surgery, are controlled. CONTEXT: It is unknown whether oncology patients who develop a venous thromboembolism after a complete curative resection are at the same survival disadvantage as oncology patients with a spontaneous VTE. METHODS: A retrospective case control study was conducted at Memorial Sloan-Kettering Cancer Center. Years of study: January 1, 2000, to December 31, 2005. Median follow-up: 24.9 months (Interquartile range 13.0, 43.0). All cancerpatients who underwent abdominal, pelvic, thoracic, or soft tissue procedures and those who developed a VTE within 30 days of the procedure were identified from a prospective morbidity and mortality database. Overall survival (OS) was calculated for the entire cohort. In the matched cohort, OS and disease-specific survival (DSS) were calculated for stages 0 to 3 and stages 0 to 2. RESULTS: A total of 23,541 cancerpatients underwent an invasive procedure and 474 (2%) had a postoperative VTE. VTEpatients had a significantly worse 5-year OS compared to no-VTEpatients (43.8% vs 61.2%; P < 0.0001); 205 VTEpatients (stages 0-3) were matched to 2050 controls by age, sex, cancer type, stage, and surgical procedure. In this matched analysis, VTEpatients continued to demonstrate a significantly worse prognosis with an inferior 5-year OS (54.7% vs 66.3%; P < 0.0001) and DSS (67.8% vs 79.5%; P = 0.0007) as compared to controls. The survival difference persisted in early stage disease (stage 0-2), with 5-year DSS of 82.9% versus 87.3% (P = 0.01). CONCLUSIONS: Postoperative VTE in oncology patients with limited disease and a complete surgical resection is associated with an inferior cancer survival. A postoperative VTE remains a poor prognostic factor, even when controlling for age, stage, cancer type, and surgical procedure further supporting an independent link between hypercoagulability and cancer survival.
Authors: Hari Nathan; Matthew J Weiss; Gerald A Soff; Michelle Stempel; Ronald P Dematteo; Peter J Allen; T Peter Kingham; Yuman Fong; William R Jarnagin; Michael I D'Angelica Journal: J Gastrointest Surg Date: 2013-10-16 Impact factor: 3.452
Authors: Mazen A Juratli; Yulian A Menyaev; Mustafa Sarimollaoglu; Alexander V Melerzanov; Dmitry A Nedosekin; William C Culp; James Y Suen; Ekaterina I Galanzha; Vladimir P Zharov Journal: Biomed Opt Express Date: 2018-10-23 Impact factor: 3.732
Authors: L Gutierrez-Sainz; V Martinez-Marin; D Viñal; D Martinez-Perez; J Pedregosa; J A Garcia-Cuesta; J Villamayor; P Zamora; A Pinto; A Redondo; B Castelo; P Cruz; O Higuera; A Custodio; A Gallego; D Sanchez-Cabrero; J de Castro-Carpeño; E Espinosa; J Feliu Journal: Clin Transl Oncol Date: 2020-11-24 Impact factor: 3.405
Authors: Sandro Barni; Gerardo Rosati; Sara Lonardi; Nicoletta Pella; Maria Banzi; Maria G Zampino; Katia F Dotti; Lorenza Rimassa; Paolo Marchetti; Evaristo Maiello; Fabrizio Artioli; Daris Ferrari; Roberto Labianca; Paolo Bidoli; Alberto Zaniboni; Alberto Sobrero; Vincenzo Iaffaioli; Sabino De Placido; Gian Luca Frassineti; Andrea Ciarlo; Angela Buonadonna; Nicola Silvestris; Elena Piazza; Lorenzo Pavesi; Mauro Moroni; Mario Clerico; Massimo Aglietta; Paolo Giordani; Francesca Galli; Fabio Galli; Fausto Petrelli Journal: Ther Adv Med Oncol Date: 2020-01-20 Impact factor: 8.168